Literature DB >> 30528647

Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.

Kan Chen1, Jianbo Ma2, Xiaoyuan Jia3, Wen Ai4, Zhongren Ma5, Qiuwei Pan6.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has recently been recognized as an important etiology contributing to the increased incidence of hepatocellular carcinoma (HCC). NAFLD, characterized by fat accumulation in the liver, is affecting at least one-third of the global population. The more aggressive form, nonalcoholic steatohepatitis (NASH), is characterized by hepatocyte necrosis and inflammation. The development of effective approaches for disease prevention and/or treatment heavily relies on deep understanding of the mechanisms underlying NAFLD to HCC development. However, this has been largely hampered by the lack of robust experimental models that recapitulate the full disease spectrum. This review will comprehensively describe the current in vitro and mouse models for studying NAFLD/NASH/HCC, and further emphasize their applications and possible future improvement for better understanding the molecular mechanisms involved in the cascade of NAFLD to HCC progression.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; In vitro model; Molecular mechanism; Mouse model; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Year:  2018        PMID: 30528647     DOI: 10.1016/j.bbcan.2018.11.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  14 in total

Review 1.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

2.  High HbA1c is a risk factor for complications after hepatectomy and influences for hepatocellular carcinoma without HBV and HCV infection.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuya Orimo; Akihisa Nagatsu; Hirofumi Kamachi; Akinobu Taketomi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

3.  Nonalcoholic fatty liver disease in CLOCK mutant mice.

Authors:  Xiaoyue Pan; Joyce Queiroz; M Mahmood Hussain
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 4.  Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring.

Authors:  Tommaso Mello; Irene Simeone; Andrea Galli
Journal:  Cells       Date:  2019-05-05       Impact factor: 6.600

5.  Predictive value and clinical significance of increased SSAT-1 activity in healthy adults.

Authors:  Paramjit S Tappia; Andrew W Maksymiuk; Daniel S Sitar; Parveen S Akhtar; Nazrina Khatun; Rahnuma Parveen; Rashiduzzaman Ahmed; Rashid B Ahmed; Brian Cheng; Gina Huang; Horacio Bach; Brett Hiebert; Bram Ramjiawan
Journal:  Future Sci OA       Date:  2019-07-01

6.  Effects of intermittent fasting on liver physiology and metabolism in mice.

Authors:  Jianbo Ma; Yan Cheng; Qiang Su; Wen Ai; Ling Gong; Yueying Wang; Linhao Li; Zhongren Ma; Qiuwei Pan; Zilin Qiao; Kan Chen
Journal:  Exp Ther Med       Date:  2021-07-05       Impact factor: 2.447

7.  ApoM is an important potential protective factor in the pathogenesis of primary liver cancer.

Authors:  Yaping Bai; Wenjun Pei; Xiao Zhang; Huihao Zheng; Changchun Hua; Jiao Min; Lisheng Hu; Shuangqiu Du; Zuyue Gong; Jialin Gao; Yao Zhang
Journal:  J Cancer       Date:  2021-06-04       Impact factor: 4.207

8.  Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis.

Authors:  Miao Fang; Min Yao; Jie Yang; Wen-Jie Zheng; Li Wang; Deng-Fu Yao
Journal:  World J Gastrointest Oncol       Date:  2020-01-15

9.  Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Sana Raza; Sangam Rajak; Baby Anjum; Rohit A Sinha
Journal:  Hepatoma Res       Date:  2019-12-11

Review 10.  Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.

Authors:  Wei Jia; Cynthia Rajani; Hongxi Xu; Xiaojiao Zheng
Journal:  Protein Cell       Date:  2020-08-14       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.